Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Existing drug offers targeted treatment for aggressive breast cancer
As per the study which was published in the journal Cancer Research, the clinical trial showed positive results of the drug palbociclib in a specific type of triple
As per the study which was published in the journal Cancer Research, the clinical trial showed positive results of the drug palbociclib in a specific type of triple
BIO 300 is Humanetics’ drug candidate which is expected to counteract and relieve not only severe and chronic inflammatory diseases but also radiation toxicities. The progressive pulmonary inflammation
The approval for Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) was based on the positive results from SYGMA 1 and SYGMA 2 Phase III trials, which evaluated the efficacy of the
Merck said that the review findings of the clinical trials showed that V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen
Through the expanded agreement, Humanigen will now gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA) for the development of lenzilumab as
The Sputnik V vaccine was registered under the emergency use authorisation procedure based on the results from the Russian Phase III clinical trials on more than 33,000 people.
The rapidly fast-spreading B.1.1.7 lineage, a variant strain of SARS-CoV-2 detected initially in the UK, has ten mutations located in the spike protein. The two firms had earlier
Akron Biotech will produce the Human AB Serum using Octapharma’s solvent-detergent treated human plasma, Octaplas. The Octaplas viral inactivation and production process includes several independent and complementary steps
As part of the development, Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have signed an agreement to
Novartis and GSK have agreed to provide £2.8m ($3.6m) for the Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT) project (Project Africa GRADIENT), over the next